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Likelihood of Spontaneous Conversion of Atrial Fibrillation to
Sinus Rhythm
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Objectives. We sought to determine the likelihood and predic-
tors of spontaneous conversion to sinus rhythm of recent-onset
atrial fibrillation (symptoms <72 h).
Background. Although spontaneous conversion of recent-onset
atrial fibrillation is common, the likelihood and clinical and
echocardiographic predictors have not been fully defined. Such
data would be important for management of patients in whom
early cardioversion is desired: Cardioversion could be delayed in
patients with a high likelihood of spontaneous conversion, and it
could be expeditiously pursued if spontaneous conversion is
unlikely.
Methods. We screened 1,822 consecutive adults admitted to the
hospital with atrial fibrillation and prospectively identified 356
patients (45% male, mean age 6 SD 68 6 16 years) with atrial
fibrillation of <72-h duration. The occurrence of spontaneous
conversion to sinus rhythm and clinical and echocardiographic
data were identified through retrospective chart review.
Results. Spontaneous conversion to sinus rhythm occurred in
68% of the study group (n 5 242; 95% confidence interval [CI]
63% to 73%). Among patients with spontaneous conversion, the
total duration of atrial fibrillation was <24 h in 159 (66%), 24 to
48 h in 42 (17%) and >48 h in 41 (17%) (p < 0.001). Logistic
regression analysis of clinical data identified presentation <24 h
from onset of symptoms as the only predictor of spontaneous
conversion (odds ratio 1.8, 95% CI 1.4 to 2.4, p < 0.0001). Normal
left ventricular systolic function was more common among pa-
tients with spontaneous conversion (p 5 0.03), but it was not an
independent predictor of conversion. Left atrial dimension was
similar between groups.
Conclusions. Spontaneous conversion to sinus rhythm occurs in
almost 70% of patients presenting with atrial fibrillation of <72-h
duration. Presentation with symptoms of <24-h duration is the
best predictor of spontaneous conversion.
(J Am Coll Cardiol 1998;31:588–92)
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Atrial fibrillation is the most commonly encountered sustained
arrhythmia, occurring in 0.4% to 2.0% of the population (1)
and increasingly prevalent with advancing age (2). It has been
estimated that .260,000 hospital admissions annually are
related to atrial fibrillation (3). For patients who are in
hemodynamically stable condition, initial therapy for this
arrhythmia includes ventricular rate control with subsequent
consideration of pharmacologic or direct current (DC) cardio-
version to relieve symptoms and improve cardiac output (4–6).
If the duration of atrial fibrillation is ,48-h, early cardiover-
sion has been advocated (4–6) and shown to be safe (7).
Although data from small series (8–13) have suggested that a
significant proportion of patients presenting with atrial fibril-
lation will have spontaneous conversion to sinus rhythm, to our
knowledge, no data from large consecutive series have been
reported. In addition, clinical and echocardiographic indexes
predictive of spontaneous conversion have not been fully
examined. Because both pharmacologic and electrical cardio-
version are expensive, time-consuming and potentially hazard-
ous interventions (14–18), the ability to identify patients in
whom spontaneous conversion is likely would help in the
clinical management of atrial fibrillation. For patients in whom
cardioversion is desired, active cardioversion could be delayed
for those with a high likelihood of spontaneous conversion,
whereas patients with a low likelihood of spontaneous conver-
sion could be directed to expeditious pharmacologic or elec-
trical cardioversion.
Accordingly, we studied a consecutive series of patients
admitted to the hospital with new-onset (,72 h) atrial fibril-
lation to determine the likelihood of spontaneous conversion
to sinus rhythm and to identify clinical and echocardiographic
indexes predictive of such conversion.
Methods
Patients. We prospectively screened 1,214 consecutive
adult patients admitted to the Beth Israel Hospital from
January 1, 1990 through September 25, 1995 and 608 consec-
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utive patients admitted to the University of Connecticut
Health Center from September 28, 1991 through April 29,
1996 with a diagnosis that included atrial fibrillation to identify
those with a clinically estimated duration of atrial fibrillation of
,72 h. We have previously reported data from a subset of this
1,822-patient cohort to assess for occurrence of cardioversion-
related thromboembolic events in patients with atrial fibrilla-
tion of ,48-h duration (7). Case identification criteria and
methodology of that analysis have been described elsewhere
and were different from those of the present report. For the
present analysis, onset of atrial fibrillation was defined as a
new, abrupt and clearly recognizable onset of symptoms,
including palpitation, dyspnea, angina or dizziness alone or in
combination. Exclusion criteria included 1) atrial fibrillation of
uncertain duration or clinically suggestive of .72-h duration,
2) concomitant antiarrhythmic therapy at the time of presen-
tation (e.g., quinidine, procainamide, flecainide, propafenone,
sotalol or amiodarone), and 3) performance of a transesoph-
ageal echocardiography–guided approach for active cardiover-
sion. There were 356 patients who met entry criteria, and data
from a retrospective review of their hospital and clinic records
are included in this report.
Clinical and echocardiographic indexes. Clinical and echo-
cardiographic data retrieved from the patient’s hospital and
clinic records included age, gender, condition predisposing to
atrial fibrillation (hypertension, coronary artery disease, exces-
sive alcohol consumption, rheumatic heart disease, pulmonary
embolism, hyperthyroidism, infection), history of previous
atrial fibrillation, history of previous myocardial infarction, and
congestive heart failure (CHF) on presentation. Cardiovascu-
lar medications, including beta-adrenergic receptor antago-
nists, calcium channel blocking agents or digoxin taken before
presentation as well as those added during the index hospital
stay were noted. When available, echocardiographic data,
including M-mode left atrial dimension (19) and left ventric-
ular systolic function (defined as abnormal if there were
regional or global wall motion abnormalities), were also re-
corded.
Conversion of atrial fibrillation. For patients with conver-
sion to sinus rhythm, the duration of atrial fibrillation was
estimated from the initial onset of the acute symptoms until
the time of the in-hospital conversion, as documented by
12-lead electrocardiography or rhythm strip. Conversion was
defined as spontaneous if it occurred before or after the
administration of only rate-controlling medications (beta-
adrenergic receptor antagonists, calcium channel blockers or
digoxin). Conversion was defined as active if it occurred after
administration of one or more antiarrhythmic medications
(e.g., quinidine, procainamide, flecainide, propafenone, sotalol
or amiodarone) or after DC countershock. Patients with
nonspontaneous conversion included those who underwent
active cardioversion (electrical or pharmacologic) and those
who had sustained atrial fibrillation throughout the index
hospital admission.
Data analysis. All data are reported as mean value 6 1 SD.
A forward logistic regression analysis model was constructed to
assess the predictive value of individual clinical and echocar-
diographic indexes for spontaneous conversion of atrial fibril-
lation (SPSS for Windows, version 6.0, SPSS Inc.). In this
forward stepwise selection of covariates, removal testing is
based on the probability of the likelihood-ratio statistic based
on the maximal partial likelihood estimates. For entry in the
model a cutoff p value of 0.05 was used and for removal from
it a cutoff value of 0.1. The model allowed for a maximum of 20
iterations. The dependent variable was spontaneous conver-
sion to sinus rhythm; covariates included age, gender, predis-
posing condition, history of previous atrial fibrillation, history
of previous myocardial infarction, class of ventricular rate-
controlling agent used (before or during the index admission),
presence of CHF on presentation and duration of atrial
fibrillation ,24 h at presentation. For patients with trans-
thoracic echocardiographic data, a separate analysis included
left ventricular systolic dysfunction and left atrial enlargement
as covariates together with those listed previously. On the basis
of results of the logistic regression analysis, the odds ratio
(OR) and 95% confidence interval (CI) were calculated.
Results
Patients. The study group included 356 adults (159 [45%]
male, 197 [55%] female) with a mean age of 68 6 16 years. The
clinical characteristics and echocardiographic data for the entire
group are summarized in Table 1. An underlying systemic condi-
tion predisposing to atrial fibrillation was identified in 275 pa-
tients (79%), no underlying condition was identified in 81 patients
(23%). Forty percent of patients had a history of prior atrial
fibrillation, and the clinically estimated duration of atrial
fibrillation was ,24 h in 292 patients (82%). Two hundred
thirty-three patients (65%) were receiving atrioventricular
(AV)-node blocking agents at the time of presentation to the
hospital. After admission, digoxin (n 5 138, 39%), calcium
channel blockers (n 5 105, 30%) or beta-adrenergic receptor
antagonists (n 5 82, 23%) were added. Transthoracic echocar-
diographic data were available for 275 patients (77%) and are
also summarized in Table 1. Left ventricular systolic dysfunc-
tion was present in 70 patients (25%), and 49% of patients had
left atrial enlargement (long axis dimension .4.0 cm).
Clinical outcomes and predictors of spontaneous conver-
sion. Spontaneous conversion to sinus rhythm occurred in
68% (n 5 242; 95% CI 63% to 73%) of the study group.
Among patients with spontaneous conversion, the total dura-
tion of atrial fibrillation was ,24 h in 159 patients (66%), 24 to
Abbreviations and Acronyms
AV 5 atrioventricular
CHF 5 congestive heart failure
CI 5 confidence intervals
DAAF 5 Digitalis in Acute Atrial Fibrillation (trial)
DC 5 direct current
OR 5 odds ratio
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48 h in 42 (17%) and .48 h in 41 (17%) (p , 0.001). Of 292
patients presenting with atrial fibrillation of ,24-h duration,
spontaneous conversion to sinus rhythm occurred in 213
(73%). In contrast, only 45% (29 of 64) of those with onset of
atrial fibrillation between 24 and 72 h before presentation had
spontaneous termination of the arrhythmia (p , 0.001).
Logistic regression analysis of clinical data identified dura-
tion of atrial fibrillation ,24 h at presentation as the only
clinical predictor of spontaneous conversion to sinus rhythm
(OR 1.8; 95% CI 1.4 to 2.4, p , 0.0001). Age, gender and
predisposing systemic condition for atrial fibrillation were not
predictive of spontaneous conversion. The use of digoxin,
beta-blockers or calcium channel blockers at the time of
presentation or the subsequent administration of these agents
was not predictive of spontaneous conversion. When echocar-
diographic data were also included, the duration of atrial
fibrillation ,24 h at presentation remained the best predictor
of spontaneous conversion (OR 2.2; 95% CI 1.6 to 3.1, p ,
0.0001).
Echocardiographic left atrial enlargement was not predic-
tive of spontaneous conversion to sinus rhythm. Preserved left
ventricular systolic function was more common among patients
with spontaneous conversion (p 5 0.03) but was also not an
independent predictor of such conversion.
Ninety-five patients (27%) in the study group received
therapies for active cardioversion; specific antiarrhythmic
treatment was instituted in 82 patients, including quinidine
(n 5 43), procainamide (n 5 29) or other antiarrhythmic
agents (n 5 10). Fifteen patients continued to have atrial
fibrillation throughout the hospital stay.
Discussion
Immediate electrical cardioversion is indicated whenever
atrial fibrillation is associated with hemodynamic compromise.
In patients in stable condition, however, a less aggressive
strategy is generally used, beginning with ventricular rate
control and followed by elective pharmacologic or electrical
cardioversion to relieve symptoms and improve cardiac output
(4–6). Because both pharmacologic and electrical cardiover-
sion have associated risks (14–17), identifying patients in
whom spontaneous conversion is likely to occur and avoiding
active intervention might decrease cardioversion-related mor-
bidity. In this consecutive study of 356 patients with atrial
fibrillation, almost 70% of patients had spontaneous conver-
sion to sinus rhythm, and a duration of atrial fibrillation ,24 h
at presentation was identified as the best clinical predictor of
spontaneous conversion. Other clinical and echocardiographic
Table 1. Comparison of Clinical and Echocardiographic Indexes Among Patients Who Did and Did








(n 5 114) Chi-Square
p
Value
Age (yr) 68 6 17 69 6 16 0.69
Female 138 (57%) 59 (52%) 0.90 0.34
Underlying systemic disorder
Hypertension 105 48 0.01 0.91
Ischemic heart disease 70 33 0.02 0.90
Prior myocardial infarction 23 12 0.01 0.91
Infection 14 13 2.74 0.10
Rheumatic heart disease 2 4 1.94 0.16
Pericarditis 1 2 0.45 0.50
Pulmonary embolus 2 0 0.33 0.57
Hyperthyroidism 2 0 0.05 0.83
History of prior atrial fibrillation 97 47 0.01 0.93
Duration of atrial fibrillation ,24 h at presentation 213 79 17.16 , 0.001
AV node blocking agent
At presentation
Beta-adrenergic receptor antagonist 52 32 1.52 0.22
Calcium channel blocker 52 28 0.26 0.61
Digoxin 42 27 1.60 0.21
Added after presentation
Beta-adrenergic receptor antagonist 57 25 0.04 0.84
Calcium channel blocker 73 32 0.08 0.78
Digoxin 97 41 0.39 0.53
Transthoracic echocardiographic data (n 5 275)
Left atrial dimension (n 5 246) (cm) 4.1 6 0.7 4.2 6 0.8 0.25
Left atrial dimension .4.0 cm 82 (47%) 38 (54%) 0.90 0.34
Left ventricular systolic dysfunction 40 (21.3%) 30 (34%) 4.79 0.03
Data are presented as mean value 6 SD or number (%) of patient group. AV 5 atrioventricular.
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variables such as age, gender, left atrial enlargement, left
ventricular systolic dysfunction or use of ventricular rate–
controlling agents were not predictive of spontaneous conver-
sion.
Comparison with previous studies. Previous data on spon-
taneous conversion of atrial fibrillation to sinus rhythm have
been derived from smaller series that focused on the utility of
specific AV node blocking agents or antiarrhythmic medica-
tions for promoting cardioversion. With the possible exception
of sotalol, agents such as digoxin, beta-adrenergic receptor
antagonists or calcium channel blockers are effective for
ventricular rate control but ineffective for converting atrial
fibrillation to sinus rhythm (20–25). Previously, Falk and
colleagues (8), examining the efficacy of digoxin for converting
atrial fibrillation in a study of 36 patients, reported that 44% of
the patients in the placebo arm had spontaneous conversion,
compared with 50% of patients randomized to digoxin. Similar
results were recently reported by the Digitalis in Acute Atrial
Fibrillation (DAAF) investigators (12). In that multicenter
prospective study of digoxin versus placebo for conversion of
recent atrial fibrillation, there was no significant difference
(51% vs. 46%, respectively) in the rate of conversion to sinus
rhythm. The finding of both studies that digoxin does not
promote conversion to sinus rhythm is consistent with our data.
The slightly lower spontaneous conversion rates reported both
by Falk et al. (8) and the DAAF investigators (12) (as
compared with those in the current study) is probably related
to differences in patient population. The previous studies
included patients with atrial fibrillation of up to 7 days’
duration, whereas our study included only those with atrial
fibrillation of ,72-h duration. We chose to study patients with
atrial fibrillation of shorter duration as they represent the
clinical population for whom early cardioversion is advocated
(4–6). For those with atrial fibrillation of .72-h duration,
active conversion is advocated either after the patient has had
3 to 4 weeks of warfarin therapy or after the patient has been
treated with heparin and results of a transesophageal echocar-
diogram are negative for intracardiac thrombi (26–28).
Galve and colleagues (9) examined the utility of amioda-
rone versus placebo for acute short-term conversion of atrial
fibrillation to sinus rhythm in 50 patients. Conversion occurred
in 68% of those receiving amiodarone versus 60% of patients
given placebo (p 5 NS). In concert with our results, these
investigators noted that shorter duration of atrial fibrillation
was associated with conversion (duration of 12 h for patients
with spontaneous conversion vs. 41 h for patients without
conversion). In contrast to our data, however, they also found
that younger age, smaller left atrial size and absence of heart
failure were predictive of spontaneous conversion.
Weiner and colleagues (11), reported data from a 50-
patient randomized study comparing propafenone with vera-
pamil (as a control) in the treatment of recent onset atrial
fibrillation (,2 weeks’ duration). In the verapamil arm, 9
(41%) of 22 patients had spontaneous conversion to sinus
rhythm after 48 h. Among a subset of patients in their study
with atrial fibrillation for ,24 h, 7 (58%) of 12 patients had
spontaneous conversion, a rate similar to the 73% rate in our
study. When the duration of atrial fibrillation was .24 h, only
2 (20%) of 10 patients had spontaneous conversion. In another
study (13) comparing short-term (3 and 8 h) conversion rates
in patients with recent onset atrial fibrillation (,7 days)
receiving propafenone or placebo, .50% of the patients
receiving placebo had conversion to sinus rhythm. Although
propafenone was more efficacious than placebo for conversion
to sinus rhythm (78% vs. 56%, p 5 0.02), among those with
conversion the mean duration of atrial fibrillation from oral
ingestion of therapy to arrhythmia conversion was identical in
the two groups (181 min). Presence of heart disease (including
cardiomyopathy, valvular, congenital and coronary disease)
was associated with lower rates of short-term spontaneous
conversion.
Our finding that atrial fibrillation of ,24 h duration at
presentation was the best predictor of conversion to sinus
rhythm is consistent with the recently described, elegant goat
model of atrial fibrillation reported by Wijffels and co-workers
(29). They reported that the length of artificially induced atrial
fibrillation correlated with the duration of sustained atrial
fibrillation once artificial atrial fibrillation was terminated.
After 2 weeks of induced atrial fibrillation, long-term sustained
atrial fibrillation was the most likely outcome. In contrast,
short episodes of induced atrial fibrillation led to prompt
spontaneous conversion once atrial fibrillation was terminated.
Electrophysiologic investigation in that animal model revealed
a direct correlation between atrial effective refractory period
and duration of the arrhythmia. As suggested by these authors
(29), atrial fibrillation “begets atrial fibrillation” by promoting
electrophysiologic conditions favorable for propagation of the
arrhythmia, providing a compelling explanation for the rela-
tion between likelihood of spontaneous conversion to sinus
rhythm and duration of atrial fibrillation.
Our study, in contrast to that of Galve et al. (9), did not
identify left atrial size as a predictor for spontaneous conver-
sion. However, our findings agree with those of Dittrich et al.
(30), who also found no relation between age or left atrial size
and spontaneous conversion.
Limitations of the study. In our study cohort, many pa-
tients who did not have spontaneous conversion to sinus
rhythm in a timely manner received active therapies (pharma-
cologic or electrical cardioversion) to restore sinus rhythm. By
the definition employed in our study, these patients were
classified as having nonspontaneous conversion. It is possible,
however, that some of these patients would have had sponta-
neous conversion if they had not received these active thera-
pies. Because of the retrospective nature of our analysis, we
could not adjust for this confounder. Thus, our data may
underestimate the true incidence of spontaneous conversion, a
possibility that further underscores the need to have a placebo
group in trials of antiarrhythmic agents for conversion of atrial
fibrillation to sinus rhythm.
Conclusions. Spontaneous conversion to sinus rhythm oc-
curs in almost 70% of patients with atrial fibrillation of ,72-h
duration, and a clinical duration of atrial fibrillation of ,24 h
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at presentation is the best predictor of spontaneous conver-
sion. The high rate of spontaneous conversion highlights the
importance of having a control group when assessing the
efficacy of active cardioversion strategies.
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